Ionis Pharmaceuticals, Inc. $IONS Shares Purchased by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP boosted its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report) by 51.8% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 267,215 shares of the company's stock after buying an additional 91,180 shares during the period. Dimensional Fund Advisors LP owned approximately 0.16% of Ionis Pharmaceuticals worth $20,056,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the company. Brown Brothers Harriman & Co. purchased a new stake in shares of Ionis Pharmaceuticals in the fourth quarter valued at about $27,000. Quarry LP purchased a new position in Ionis Pharmaceuticals during the third quarter worth about $38,000. Johnson Financial Group Inc. acquired a new stake in Ionis Pharmaceuticals in the third quarter valued at about $44,000. Laurel Wealth Advisors LLC acquired a new stake in Ionis Pharmaceuticals in the fourth quarter valued at about $47,000. Finally, Hilton Head Capital Partners LLC purchased a new stake in Ionis Pharmaceuticals in the 4th quarter valued at approximately $47,000. 93.86% of the stock is owned by institutional investors and hedge funds.

Ionis Pharmaceuticals Price Performance

IONS stock opened at $54.49 on Friday. The firm has a 50 day moving average of $67.81 and a 200-day moving average of $73.86. Ionis Pharmaceuticals, Inc. has a 12-month low of $40.03 and a 12-month high of $86.74. The company has a current ratio of 7.89, a quick ratio of 7.73 and a debt-to-equity ratio of 3.07. The company has a market cap of $9.06 billion, a price-to-earnings ratio of -15.75 and a beta of 0.41.

Analyst Ratings Changes

Several equities analysts have issued reports on the company. Morgan Stanley dropped their target price on Ionis Pharmaceuticals from $130.00 to $110.00 and set an "overweight" rating on the stock in a research report on Friday, July 10th. Wolfe Research reissued a "peer perform" rating on shares of Ionis Pharmaceuticals in a report on Thursday, July 16th. Needham & Company LLC decreased their price target on Ionis Pharmaceuticals from $105.00 to $86.00 and set a "buy" rating on the stock in a research note on Thursday, July 9th. Raymond James Financial set a $87.00 price objective on Ionis Pharmaceuticals in a report on Thursday, July 9th. Finally, Bank of America raised their target price on Ionis Pharmaceuticals from $100.00 to $111.00 and gave the company a "buy" rating in a report on Thursday, April 9th. Eighteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, Ionis Pharmaceuticals presently has an average rating of "Moderate Buy" and a consensus target price of $94.65.

Ionis Pharmaceuticals News Summary

Here are the key news stories impacting Ionis Pharmaceuticals this week:

• Positive Sentiment: JPMorgan reportedly expects Ionis Pharmaceuticals’ stock price to rise, providing a bullish signal for investors. The positive view may reflect confidence in the company’s drug pipeline and longer-term growth prospects. Ionis Pharmaceuticals Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $115 price target, well above recent trading levels. The firm also modestly improved its fiscal 2026 EPS forecast to a loss of $3.41 per share from a projected loss of $3.45, and its estimate remains better than the current-year consensus loss of $3.67. HC Wainwright Analysts Decrease Earnings Estimates for IONS
• Neutral Sentiment: The analyst’s projections imply that Ionis is still expected to report losses in each listed quarter, including estimated EPS of negative $1.14 for Q3 2026 and negative $1.02 for Q4 2026. The company’s strong liquidity, reflected in a quick ratio above 7, provides financial flexibility, but profitability remains a key investor concern.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for Q3 2026, Q4 2026, Q1 2027, Q2 2027 and full-year 2027. The FY2027 forecast was lowered to a loss of $1.27 per share from $1.11, while the Q4 2026 estimate declined to a loss of $1.02 from $0.83. These revisions suggest weaker near-term earnings expectations and could weigh on the stock. HC Wainwright Analysts Decrease Earnings Estimates for IONS

Insider Transactions at Ionis Pharmaceuticals

In related news, EVP Holly B. Kordasiewicz sold 60,846 shares of Ionis Pharmaceuticals stock in a transaction on Friday, June 12th. The stock was sold at an average price of $73.41, for a total transaction of $4,466,704.86. Following the completion of the transaction, the executive vice president directly owned 22,458 shares of the company's stock, valued at approximately $1,648,641.78. The trade was a 73.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP C Frank Bennett sold 15,000 shares of the business's stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $85.46, for a total value of $1,281,900.00. Following the sale, the executive vice president owned 75,018 shares in the company, valued at approximately $6,411,038.28. The trade was a 16.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 233,163 shares of company stock worth $18,316,551 over the last ninety days. 1.81% of the stock is currently owned by corporate insiders.

Ionis Pharmaceuticals Profile

Ionis Pharmaceuticals, Inc is a biotechnology company focused on the discovery and development of RNA-targeted therapies designed to modulate gene expression. The company's proprietary antisense oligonucleotide (ASO) technology enables the selective binding of short synthetic strands of nucleic acids to messenger RNA (mRNA), thereby inhibiting or altering the production of disease-causing proteins. Ionis' pipeline spans a range of therapeutic areas, including neurological disorders, cardiovascular conditions, metabolic diseases and rare genetic disorders.

Since its founding in 1989 by Dr.

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source